Premium
Direct In Vivo Xenograft Tumor Model for Predicting Chemotherapeutic Drug Response in Cancer Patients
Author(s) -
RubioViqueira B,
Hidalgo M
Publication year - 2009
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2008.200
Subject(s) - in vivo , medicine , cancer , drug response , drug , chemotherapeutic drugs , cancer research , pharmacology , oncology , biology , microbiology and biotechnology
It is estimated that the development of a new anticancer agent costs US$800 million to 1 billion and takes more than a decade between conception and approval. 1 However, 90% of novel antineoplastic drugs fail in the clinic despite evidence of antitumor efficacy in classical preclinical models. 2 This raises serious concerns as to whether such models are predictive of drug efficacy in humans, particularly in the current era of new targeted therapies, and supports the development of alternative approaches. Clinical Pharmacology & Therapeutics (2009); 85 , 2, 217–221 doi: 10.1038/clpt.2008.200